What does pre-clinical research on medicinal mushrooms examine in the context of cancer?

Pre-clinical research (in vitro and in animal models) examines how certain compounds in mushrooms — mainly β-glucans and triterpenes — interact with immune-system cells and with cellular pathways. These are basic research directions only, not evidence of therapeutic efficacy in humans. Medicinal-mushroom extracts are dietary supplements; they are not a cancer treatment and not a substitute for medical care.

Are medicinal mushrooms a cancer treatment or a substitute for chemotherapy?

No. Medicinal-mushroom extracts are dietary supplements only. They are not intended to diagnose, treat, cure, or prevent any disease, and are not a substitute for chemotherapy, radiation, surgery, or any oncology treatment. Cancer patients must consult their treating physician before taking any supplement.

What is the difference between PSK, PSP and Lentinan and the mushroom extract sold as a supplement?

PSK (Krestin), PSP and Lentinan are isolated, regulated pharmaceutical compounds that were developed, approved and administered within a medical setting in Japan. They are not the same as the whole mushroom extract sold as a dietary supplement, and the clinical data on them cannot be extrapolated to food supplements.

Which mushrooms are studied in an oncology context?

Among the mushrooms studied in the literature are Trametes (Turkey Tail), reishi, shiitake, maitake and chaga. It is important to distinguish between research on isolated, regulated compounds (such as PSK from Trametes) and the whole mushroom extract. The research examines mechanisms — it does not establish a therapeutic indication.

Is eating culinary mushrooms enough to obtain a research effect?

Eating edible mushrooms is part of a balanced, healthy diet. However, no therapeutic indication should be inferred from it. Concentrated extracts provide a higher concentration of β-glucans, but they too are dietary supplements only and are not a treatment for any disease.

Is it safe to combine mushroom extracts with oncology treatment or medication?

Because of possible interactions with the immune system, with blood thinners and with oncology treatments, it is essential to consult a physician before combining any supplement. This is especially true for cancer patients, pregnant or breastfeeding women, people taking medication, and transplant patients.

Medicinal Mushrooms and Cancer Research: What Pre-Clinical Science Examines

Important — please read before continuing: this is an educational review, not medical advice

The article before you is an educational review of a field of research only. It does not constitute medical advice, a diagnosis, or a therapeutic indication. Medicinal-mushroom extracts are dietary supplements — they are not a cancer treatment, they do not cure, prevent, or treat any disease, and they are not a substitute for conventional medical care.

Cancer patients, pregnant or breastfeeding women, people taking medication, and transplant patients should not change anything in their care, and are required to consult their treating physician before taking any supplement.

Certain strains of mushroom have been used in the traditional medicine of East Asia for thousands of years. In recent decades, the Western scientific community has also begun to examine them systematically — to isolate the compounds within them and describe how they behave in the laboratory. Following the attention they have received in the media, medicinal mushrooms have become one of the topics surrounded by the most confusion, empty promises, and inaccuracy.

This article was written to set the record straight. We will review honestly what pre-clinical research — that is, research in the test tube (in vitro) and in animal models — examines in the context of mushrooms and cancer, and we will equally clarify what it does not show. We will not promise you anything, and we will not make any claim that does not stand behind the regulation. If you are looking for a deep, source-based understanding without the hype — you have come to the right place.

Throughout the article we will draw a sharp distinction between two things that are easy to confuse: isolated, regulated pharmaceutical compounds (such as PSK, PSP and Lentinan, which were developed and approved as drugs in Japan) and the whole mushroom extract sold as a dietary supplement. These are two entirely different worlds, and mixing them up is the source of most of the misunderstandings in this field.

Why are medicinal mushrooms in the focus of scientific research?

When people talk about mushrooms and cancer, many immediately think of “alternative medicine” or “magic solutions.” The scientific reality is different and more complex. Medicinal mushrooms are studied because they contain families of unique molecules that are not common in ordinary food, and that interest researchers in the fields of immunology and biochemistry.

It is important to make the limits of the knowledge clear: most of the interesting findings come from pre-clinical research. A finding in a test tube or in a mouse does not prove efficacy in humans, and often does not translate to clinical reality at all. That is why every description of a mechanism in this article is framed as “what the research examines” — and not as “what the mushroom does” in your body. For a deeper look at the scientific terms we mention, see the glossary of medicinal mushrooms, extraction and related concepts, and for a broad overview of the field — the complete guide to medicinal mushrooms.

The active components the research focuses on

The scientific interest in medicinal mushrooms stems largely from their rich chemical composition. These are the main groups of compounds the research examines:

Polysaccharides (β-glucans): complex sugars considered the central component in the research. β-glucans are studied in the context of supporting and balancing immune-system function (a structure-function context). The research examines how they bind to receptors on immune cells — a topic discussed at length in the glossary. We publish the β-glucan levels in our extracts with full transparency; see the transparency page and the β-glucan lab tests.
Triterpenes: a group of compounds studied in the context of anti-inflammatory and antioxidant activity. Some pre-clinical research examines their effect on cellular pathways in laboratory models — preliminary findings that do not constitute evidence of efficacy in humans.
Phenolic compounds and flavonoids: antioxidants studied in the context of reducing oxidative stress at the cellular level. This is a context of general health, not of treating a disease.
Lectins, enzymes and peptides: a wide range of additional molecules that research is still characterizing, each with its own activity profile under laboratory conditions.

The scientific interest lies not in any single component but in the combination among them. That said — understanding a mechanism in the laboratory does not guarantee a result in the human body, and that is precisely the caution that characterizes responsible research.

What pre-clinical research examines: the mechanisms studied (and the limits of the knowledge)

The advantage of a scientific approach is that it distinguishes between “what is examined” and “what is proven.” When it comes to mushrooms and cancer, the pre-clinical literature describes several research directions. It is important to read them as open research questions — not as properties of a supplement. None of the following mechanisms establishes a therapeutic claim, and none of them describes what an extract will do in your body.

Regulation and support of immune-system function (structure-function context): this is the most-studied direction. β-glucans are examined as “immunomodulators” — molecules that the research studies in the context of balancing immune activity. Pre-clinical research describes binding to receptors (such as Dectin-1) on immune cells such as macrophages and NK cells. Important: this is a description of a molecular mechanism in the laboratory, in the context of supporting and balancing immune function — not a claim that the mushroom “destroys” any cells in your body.
Effect on cell division in laboratory models: one of the topics pre-clinical research examines is how certain compounds affect the rate of cell division in cell cultures and animal models. These are laboratory findings in a highly controlled environment; they cannot be extrapolated directly to humans, and they do not constitute evidence of therapeutic efficacy.
Apoptosis (programmed cell death) in cell cultures: apoptosis is a built-in cellular mechanism. Some pre-clinical research examines how certain compounds affect apoptotic pathways in cell cultures. Again — this is a molecular research context in the laboratory, which does not describe a process that occurs in the body as a result of taking a supplement.
Angiogenesis processes in experimental models: angiogenesis (the formation of blood vessels) is a basic biological process studied in many contexts. Some of the pre-clinical literature examines the effect of mushroom compounds on this process under laboratory conditions — a preliminary research direction only.
Quality of life and side effects — a complementary-medicine context (early clinical research on isolated compounds): some of the human research in this area was actually conducted on isolated, regulated compounds (see the next section), and examined questions of quality of life and side effects among patients who received standard oncology treatment. These findings belong to the pharmaceutical compounds and not to the dietary supplement, and do not constitute a recommendation to combine any supplement with treatment. Any question of combination — for the treating physician only.

A critical distinction: isolated pharmaceutical compounds ≠ the supplement we sell

A significant portion of the oncology data in the literature refers to PSK (Krestin), PSP and Lentinan — these are isolated, regulated pharmaceutical compounds that were developed, purified, approved, and sometimes even administered within a supervised medical setting in Japan. They are not the whole mushroom extract sold as a dietary supplement. No conclusion about food supplements should be drawn from the clinical data on these compounds.

The mushrooms studied in the context of cancer — and how to read the evidence correctly

In the scientific literature there are several strains that receive considerable research attention. It is important to read each paragraph below as a description of research directions — and not as a list of “benefits” of a supplement. Pay particular attention to the distinction between isolated, regulated compounds and the whole mushroom.

Trametes versicolor (Turkey Tail): among the most-studied mushrooms in the oncology context, mainly because of two polysaccharides — PSK (Krestin) and PSP. Note: PSK and PSP are isolated, regulated pharmaceutical compounds that were registered in Japan as medical preparations — not the Trametes extract sold as a supplement. A Cochrane review and other reviews examined the use of these preparations as an adjunct in medical settings. The data belong to the regulated compounds only, and cannot be extrapolated to a dietary supplement. For more on the science, see our Turkey Tail science page.
Shiitake (Lentinula edodes): contains the polysaccharide Lentinan. Lentinan is an isolated, regulated pharmaceutical compound developed as an injectable preparation in Japan — not the shiitake extract sold as a supplement, and certainly not oral consumption of the mushroom. The research on Lentinan belongs entirely to the isolated pharmaceutical compound.
Maitake (Grifola frondosa): studied in the context of a β-glucan fraction known as “D-Fraction”. D-Fraction is an isolated, standardized extract used in research, and is not identical to the commercial maitake extract sold as a supplement. Pre-clinical research examined its effect on cellular pathways and on immune function under laboratory conditions.
Reishi (Ganoderma lucidum): known in Chinese culture as the “mushroom of immortality.” Rich in triterpenes and β-glucans, and studied in the context of supporting and balancing immune-system function (a structure-function context) and in the context of liver health. The mechanism descriptions come mostly from pre-clinical research.
Cordyceps (Cordyceps sinensis): known in the context of energy and stamina. Pre-clinical research also examines unique molecules within it (such as cordycepin) in various cellular contexts in the laboratory. These are preliminary research directions only.
Chaga (Inonotus obliquus): which grows on birch trees in cold regions, is considered one of the world’s richest sources of antioxidants. Certain compounds within it (such as betulinic acid) are examined in pre-clinical research in cellular contexts. This is a matter of research interest and not a therapeutic indication.

These mushrooms continue to spark research interest, but the road to solid clinical conclusions is long, and the research is still ongoing. For the full picture on each strain, see the complete guide to medicinal mushrooms.

Transparency and quality: what is really in the extract — and how it is tested

The difference between a quality supplement and a worthless powder lies in transparency and testing. At Triterra Farm we send every batch to an independent external laboratory that tests purity (heavy metals, toxins) and verifies the β-glucan concentration. In independent lab tests (TÜV, 07/2025), our extracts measured β-glucan levels of Cordyceps 28.16%, Reishi 25.65%, Lion’s Mane 23.93%, and Turkey Tail + Reishi 23.21% — with no starch detected. We publish all the data openly; see the transparency page and the β-glucan lab tests.

An important clarification: these quality data refer to the composition of the supplement — that is, to the concentration of the active component — and not to any medical benefit. A quality supplement is still a dietary supplement, not a treatment.

Why an extract and not a powder?

Mushrooms have a cell wall made of chitin, which the human digestive system struggles to break down. A professional extraction process releases the β-glucans and triterpenes and produces a higher, more consistent concentration of the active components compared with a powder of ground mushroom. This is a matter of composition and component availability — not a therapeutic indication. For an explanation of the extraction concepts, see the glossary.

Questions and answers: reading the research correctly

Q: Can medicinal mushrooms replace oncology treatment?
A: Absolutely not. Medicinal-mushroom extracts are dietary supplements only; they are not a cancer treatment and are not a substitute for chemotherapy, radiation, surgery, or any medical treatment. Cancer patients are required to consult their treating physician before taking any supplement.
Q: If there is research on PSK and Lentinan, does that mean the supplement works?
A: No. PSK, PSP and Lentinan are isolated, regulated pharmaceutical compounds — not the mushroom extract sold as a supplement. No conclusion about a dietary supplement should be drawn from the research on them.
Q: Is eating culinary mushrooms “enough”?
A: Edible mushrooms are part of a healthy, balanced diet. This carries no therapeutic indication, and no conclusion about food consumption should be drawn from research on concentrated compounds.
Q: What is a responsible way to read pre-clinical research?
A: Remember that a finding in a test tube or in a mouse is an open research question — not proof regarding humans, and certainly not regarding a commercial supplement. This caution is the hallmark of responsible science.

Where is the research heading?

Despite the progress in understanding the compounds in mushrooms, significant scientific challenges remain:

The need for quality clinical research: most of the knowledge today is pre-clinical. Large-scale randomized, double-blind, placebo-controlled trials are needed to answer questions of efficacy and safety in humans. Until these exist, no therapeutic conclusions should be drawn.
Standardization of extracts: component concentrations vary between products and between batches. Transparency and independent lab testing are the way to reduce this uncertainty — which is exactly why we publish our lab tests in full.
Distinguishing an isolated compound from the whole mushroom: a central challenge is not to mix data on isolated pharmaceutical compounds (PSK/PSP/Lentinan/D-Fraction) with the whole mushroom. Such mixing is the source of most of the public’s misunderstandings.

We stand at the beginning of a fascinating field of research, but it should be approached with humility and caution. Evidence-based knowledge, not promises, is the only way forward.

Summary and sources for deeper reading

We have seen that the story of mushrooms and cancer is not a forest myth — but it is also not a story of a miracle cure. It is a living field of research, most of which is still pre-clinical, and which requires careful reading and a distinction between isolated pharmaceutical compounds and the whole mushroom extract sold as a supplement.

If you want to go deeper responsibly, these are the right resources:

General readers: the complete guide to medicinal mushrooms and the glossary of terms.
Those who want to see the data: the transparency page and the β-glucan lab tests.
Professionals and practitioners: you are welcome to the professional information space for practitioners, where the information is presented in depth and in the right context. You can also browse the frequently asked questions.

And most important of all: if you or your loved ones are coping with an illness — the only address is the treating medical team. No article, and no supplement, is a substitute for that.

Disclaimer: This content is an educational review of a field of research. Data on PSK, PSP and Lentinan refer to isolated, regulated pharmaceutical compounds, not to a mushroom extract sold as a supplement. It does not constitute a medical recommendation or a therapeutic indication. Medicinal-mushroom extracts are dietary supplements only — they are not intended to diagnose, treat, cure, or prevent any disease, and are not a substitute for treatment. Cancer patients, pregnant or breastfeeding women, people taking medication, and transplant patients are required to consult a physician before taking any supplement.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Data on isolated compounds (PSK, PSP, Lentinan) refer to regulated pharmaceutical drugs, not the extract sold as a dietary supplement. Cancer patients must consult their physician before using any supplement.*